Hologic vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Women's health medtech with $3.9B FY2024 revenue; 3D Genius Mammography market leader; Panther molecular diagnostics platform; annual screening guidelines expand mammography TAM by ~30%.
About
Hologic is a global medical technology company uniquely dedicated to women's health, founded in 1985 and headquartered in Marlborough, Massachusetts, trading on Nasdaq (HOLX). The company generated approximately $3.9 billion in revenues for fiscal year 2024 (ending September 28) under CEO Stephen MacMillan, who has led Hologic since 2013 and transformed it from a single-product mammography company into a diversified women's health platform. Hologic's four business segments serve distinct clinical needs: Diagnostics (Panther molecular testing platform, cervical health testing, and COVID-19 diagnostics), Breast Health (3D mammography, breast biopsy guidance systems, radiation therapy), Surgical (NovaSure endometrial ablation, MyoSure fibroid removal, and minimally invasive hysteroscopy), and Skeletal Health (bone density measurement).
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.